Tryptamine Therapeutics (ASX:TYP) completed the dosing of the first subject in its phase 1b study of its lead asset, TRP-8803, in obese participants, according to a Friday filing with the Australian bourse.
TRP-8803 is an intravenous-infusion formulation containing psilocin, known for its ability to induce adaptive structural and functional changes within the brain, the filing said.
The first participant received the drug, safely progressed through treatment, and was discharged shortly after the dosing follow-up was completed, according to the filing. Two more study applicants will be given TRP-8803 in the coming weeks.
Tryptamine Therapeutics shares rose more than 2% in afternoon trade Friday.
Price (AUD): $0.05, Change: $+0.001, Percent Change: +2.22%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。